Literature DB >> 22923069

Acetylcholine for male LUTS.

Steven J Weissbart1, Bilal Chughtai, Dean Elterman, Richard Lee, Alexis Te, Steven Kaplan.   

Abstract

In this review, we present the evidence on the safety and efficacy of anticholinergic therapy for men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and emphasize the data published over the past year. This review discusses two classes of medications whose mechanism of action attenuates the effect of acetylcholine on the LUT: anticholinergics and botulinum toxin. We review the randomized controlled trials that investigate the efficacy and side effects of anticholinergics when used in men with LUTS secondary to BPH. We emphasize new studies and developments that have been made in the past year.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22923069     DOI： 10.1007/s11934-012-0276-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  29 in total

1.  Counting the cost of treating benign prostatic hyperplasia.

Authors:  C L Foley; C Taylor; R S Kirby
Journal:  BJU Int       Date:  2004-02       Impact factor: 5.588

Review 2.  BPH: epidemiology and comorbidities.

Authors:  Kevin T McVary
Journal:  Am J Manag Care       Date:  2006-04       Impact factor: 2.229

Review 3.  Botulinum neurotoxin A for benign prostatic hyperplasia.

Authors:  Athanassios Oeconomou; Helmut Madersbacher
Journal:  Curr Opin Urol       Date:  2010-01       Impact factor: 2.309

4.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

5.  Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder.

Authors:  R G Charlton; A R Morley; P Chambers; J I Gillespie
Journal:  BJU Int       Date:  1999-12       Impact factor: 5.588

6.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

7.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Authors:  Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

8.  Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate.

Authors:  Ger E P M Van Venrooij; Harm H E Van Melick; Mardy D Eckhardt; Tom A Boon
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

9.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.

Authors:  Giorgio Maria; Giuseppe Brisinda; Ignazio Massimo Civello; Anna Rita Bentivoglio; Gabriele Sganga; Alberto Albanese
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

10.  Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial.

Authors:  Jae Hyun Bae; Sun Ouck Kim; Eun Sang Yoo; Kyung Hyun Moon; Yoon Soo Kyung; Hyung Jee Kim
Journal:  Korean J Urol       Date:  2011-04-22
View more
  3 in total

Review 1.  Evaluation and management of post-transurethral resection of the prostate lower urinary tract symptoms.

Authors:  Bilal Chughtai; Vannita Simma-Chiang; Steven A Kaplan
Journal:  Curr Urol Rep       Date:  2014-09       Impact factor: 3.092

Review 2.  Landmarks in BPH--from aetiology to medical and surgical management.

Authors:  Arman Kahokehr; Peter J Gilling
Journal:  Nat Rev Urol       Date:  2014-01-21       Impact factor: 14.432

3.  Predictive factors for alpha blocker use after transurethral prostatectomy: Can preoperative urodynamic outcome predict alpha blocker medication after surgery?

Authors:  Sung Jin Kim; Sung Gon Park; Sahyun Pak; Young Goo Lee; Sung Tae Cho; Ohseong Kwon
Journal:  PLoS One       Date:  2022-09-21       Impact factor: 3.752
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.